Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2022-01-28 Regulatory Filings
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ending November 30, 2021. The content is primarily an officer certification letter regarding the interim filings, without containing actual financial data or the interim report itself. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR). The document length is short (2996 characters) and it is a certification, not the full interim report.
2022-01-28 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ending November 30, 2021. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer, which is a regulatory certification confirming the accuracy and fair presentation of the interim filings. The document does not contain the actual interim financial statements or substantive financial data but is a certification letter. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (2996 characters), and it is clearly a certification rather than the full interim report.
2022-01-28 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Michael Glogauer to the advisory board of Rapid Dose Therapeutics Corp. It includes details about the appointment, stock options granted, and background information about the company. There are no financial statements, regulatory filings, or detailed reports included. The document is an announcement related to management or board changes, specifically the advisory board, which falls under Board/Management Information (MANG). The document length is 4441 characters, which is short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2022-01-05 English
News release - English.pdf
Regulatory Filings
2021-12-22 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of new leadership and advisory board members at Rapid Dose Therapeutics, along with the granting of stock options. It focuses on management changes and strategic support for commercialization efforts. There are no financial statements, regulatory filings, or detailed financial data presented. The content aligns with announcements about changes in the company's board or senior management rather than financial reports or other categories. Therefore, the document fits best under Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive management change announcement.
2021-12-15 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a product supply agreement between Rapid Dose Therapeutics and Oakland Health Limited. It discusses the strategic partnership, product orders, and company descriptions. There is no financial data, regulatory filing references, or detailed financial reports. The content is about a business development and partnership agreement, which fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, or business agreements impacting company operations. It is not an earnings release, annual report, or any other regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2021-12-09 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.